Skip to main content
Erschienen in: Inflammation Research 9/2011

01.09.2011 | Original Research Paper

Methyl-1-hydroxy-2-naphthoate, a novel naphthol derivative, inhibits lipopolysaccharide-induced inflammatory response in macrophages via suppression of NF-κB, JNK and p38 MAPK pathways

verfasst von: Jun-Yan Zhang, Hong Jin, Guang-Fa Wang, Peng-Jiu Yu, Shao-Yu Wu, Zheng-Guang Zhu, Zhong-Huang Li, Yuan-Xin Tian, Wei Xu, Jia-Jie Zhang, Shu-Guang Wu

Erschienen in: Inflammation Research | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective and design

The anti-inflammatory effect of methyl-1-hydroxy-2-naphthoate (MHNA), a novel naphthol derivative, was evaluated in the lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages.

Materials and methods

The release of nitric oxide (NO), interleukin-1beta (IL-1β) and interleukin-6 (IL-6) were detected by the Griess reagent and ELISA methods. The protein expressions of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) were examined by Western blotting. The mRNA expressions of IL-1β, IL-6, iNOS and COX-2 were determined by real-time PCR. Activation of mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-κB) pathways were detected by Western blotting, reporter gene assay and electrophoretic mobility shift assay.

Results

MHNA significantly inhibited the release of NO, IL-1β and IL-6 as well as the protein expression of iNOS and COX-2 in LPS-stimulated macrophages. It also inhibited the mRNA expression of iNOS, COX-2, IL-1β and IL-6. Further studies indicated that MHNA inhibited LPS-induced increases in NF-κB DNA-binding activity and NF-κB transcriptional activity as well as IκB-α degradation and NF-κB translocation in a dose-dependent manner. Meanwhile, the activation of p38 MAPK and c-Jun N-terminal kinases (JNK) induced by LPS were decreased by MHNA.

Conclusions

MHNA inhibits the LPS-induced inflammatory response in murine macrophages via suppression of NF-κB and MAPKs signaling pathways activation.
Literatur
1.
Zurück zum Zitat Yun KJ, Kim JY, Kim JB, Lee KW, Jeong SY, Park HJ, et al. Inhibition of LPS-induced NO and PGE2 production by asiatic acid via NF-kappa B inactivation in RAW 264.7 macrophages: possible involvement of the IKK and MAPK pathways. Int Immunopharmacol. 2008;8:431–41.PubMedCrossRef Yun KJ, Kim JY, Kim JB, Lee KW, Jeong SY, Park HJ, et al. Inhibition of LPS-induced NO and PGE2 production by asiatic acid via NF-kappa B inactivation in RAW 264.7 macrophages: possible involvement of the IKK and MAPK pathways. Int Immunopharmacol. 2008;8:431–41.PubMedCrossRef
2.
Zurück zum Zitat Feng D, Ling WH, Duan RD. Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-kappaB in macrophages. Inflamm Res. 2010;59:115–21.PubMedCrossRef Feng D, Ling WH, Duan RD. Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-kappaB in macrophages. Inflamm Res. 2010;59:115–21.PubMedCrossRef
3.
Zurück zum Zitat Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP. SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin. 2009;30:1428–35.PubMedCrossRef Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP. SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin. 2009;30:1428–35.PubMedCrossRef
4.
Zurück zum Zitat Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:21–33.PubMedCrossRef Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:21–33.PubMedCrossRef
5.
Zurück zum Zitat Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:289–95.PubMedCrossRef Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:289–95.PubMedCrossRef
6.
Zurück zum Zitat Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol. 2005;100:93–101.PubMedCrossRef Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol. 2005;100:93–101.PubMedCrossRef
7.
Zurück zum Zitat Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853–66.PubMedCrossRef Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853–66.PubMedCrossRef
8.
9.
Zurück zum Zitat Yamamoto Y, Gaynor RB. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci. 2004;29:72–9.PubMedCrossRef Yamamoto Y, Gaynor RB. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci. 2004;29:72–9.PubMedCrossRef
10.
Zurück zum Zitat Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001;107:3–6.PubMedCrossRef Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001;107:3–6.PubMedCrossRef
11.
Zurück zum Zitat Chen C, Chen YH, Lin WW. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology. 1999;97:124–9.PubMedCrossRef Chen C, Chen YH, Lin WW. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology. 1999;97:124–9.PubMedCrossRef
12.
Zurück zum Zitat Kim YH, Lee SH, Lee JY, Choi SW, Park JW, Kwon TK. Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase. Eur J Pharmacol. 2004;494:1–9.PubMedCrossRef Kim YH, Lee SH, Lee JY, Choi SW, Park JW, Kwon TK. Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase. Eur J Pharmacol. 2004;494:1–9.PubMedCrossRef
13.
Zurück zum Zitat Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem. 1999;274:30858–63.PubMedCrossRef Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem. 1999;274:30858–63.PubMedCrossRef
14.
Zurück zum Zitat Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13:85–94.PubMedCrossRef Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13:85–94.PubMedCrossRef
15.
Zurück zum Zitat Kongkathip N, Hasitapan K, Pradidphol N, Kirtikara K, Jongkona N, Kongkathip B. Synthesis of novel 2-(2′-cyclopentyl)- and 2-(2′-cyclohexyl) substituted 1-naphthol derivatives with anticyclooxygenase activity. Curr Med Chem. 2006;13:3663–74.PubMedCrossRef Kongkathip N, Hasitapan K, Pradidphol N, Kirtikara K, Jongkona N, Kongkathip B. Synthesis of novel 2-(2′-cyclopentyl)- and 2-(2′-cyclohexyl) substituted 1-naphthol derivatives with anticyclooxygenase activity. Curr Med Chem. 2006;13:3663–74.PubMedCrossRef
16.
Zurück zum Zitat Kongkathip B, Sangma C, Kirtikara K, Luangkamin S, Hasitapan K, Jongkon N, et al. Inhibitory effects of 2-substituted-1-naphthol derivatives on cyclooxygenase I and II. Bioorg Med Chem. 2005;13:2167–75.PubMedCrossRef Kongkathip B, Sangma C, Kirtikara K, Luangkamin S, Hasitapan K, Jongkon N, et al. Inhibitory effects of 2-substituted-1-naphthol derivatives on cyclooxygenase I and II. Bioorg Med Chem. 2005;13:2167–75.PubMedCrossRef
17.
Zurück zum Zitat Matsubara M, Yamachika E, Tsujigiwa H, Mizukawa N, Ueno T, Murakami J, et al. Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption. Osteoporos Int. 2010;21:1437–47.PubMedCrossRef Matsubara M, Yamachika E, Tsujigiwa H, Mizukawa N, Ueno T, Murakami J, et al. Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption. Osteoporos Int. 2010;21:1437–47.PubMedCrossRef
18.
Zurück zum Zitat Okada Y, Tsuzuki Y, Miyazaki J, Matsuzaki K, Hokari R, Komoto S, et al. Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut. 2006;55:681–8.PubMedCrossRef Okada Y, Tsuzuki Y, Miyazaki J, Matsuzaki K, Hokari R, Komoto S, et al. Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut. 2006;55:681–8.PubMedCrossRef
19.
Zurück zum Zitat Chanklan R, Mizunuma M, Kongkathip N, Hasitapan K, Kongkathip B, Miyakawa T. Identification of Saccharomyces cerevisiae Tub1 alpha-tubulin as a potential target for NKH-7, a cytotoxic 1-naphthol derivative compound. Biosci Biotechnol Biochem. 2008;72:1023–31.PubMedCrossRef Chanklan R, Mizunuma M, Kongkathip N, Hasitapan K, Kongkathip B, Miyakawa T. Identification of Saccharomyces cerevisiae Tub1 alpha-tubulin as a potential target for NKH-7, a cytotoxic 1-naphthol derivative compound. Biosci Biotechnol Biochem. 2008;72:1023–31.PubMedCrossRef
20.
Zurück zum Zitat Bauche F, Stephan JP, Touzalin AM, Jegou B. In vitro regulation of an inducible-type NO synthase in the rat seminiferous tubule cells. Biol Reprod. 1998;58:431–8.PubMedCrossRef Bauche F, Stephan JP, Touzalin AM, Jegou B. In vitro regulation of an inducible-type NO synthase in the rat seminiferous tubule cells. Biol Reprod. 1998;58:431–8.PubMedCrossRef
21.
Zurück zum Zitat Allen JB, Keng T, Privalle C. Nitric oxide and peroxynitrite production in ocular inflammation. Environ Health Perspect. 1998;106(Suppl 5):1145–9.PubMedCrossRef Allen JB, Keng T, Privalle C. Nitric oxide and peroxynitrite production in ocular inflammation. Environ Health Perspect. 1998;106(Suppl 5):1145–9.PubMedCrossRef
22.
Zurück zum Zitat Nagy G, Clark JM, Buzas EI, Gorman CL, Cope AP. Nitric oxide, chronic inflammation and autoimmunity. Immunol Lett. 2007;111:1–5.PubMedCrossRef Nagy G, Clark JM, Buzas EI, Gorman CL, Cope AP. Nitric oxide, chronic inflammation and autoimmunity. Immunol Lett. 2007;111:1–5.PubMedCrossRef
24.
Zurück zum Zitat Tripathi P, Tripathi P, Kashyap L, Singh V. The role of nitric oxide in inflammatory reactions. FEMS Immunol Med Microbiol. 2007;51:443–52.PubMedCrossRef Tripathi P, Tripathi P, Kashyap L, Singh V. The role of nitric oxide in inflammatory reactions. FEMS Immunol Med Microbiol. 2007;51:443–52.PubMedCrossRef
25.
Zurück zum Zitat Di RM, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun. 1990;172:1246–52.CrossRef Di RM, Radomski M, Carnuccio R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun. 1990;172:1246–52.CrossRef
26.
27.
Zurück zum Zitat Williams TJ. The role of prostaglandins in inflammation. Ann R Coll Surg Engl. 1978;60:198–201.PubMed Williams TJ. The role of prostaglandins in inflammation. Ann R Coll Surg Engl. 1978;60:198–201.PubMed
28.
Zurück zum Zitat Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013–7.PubMedCrossRef Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013–7.PubMedCrossRef
29.
Zurück zum Zitat Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22:347–52.PubMedCrossRef Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22:347–52.PubMedCrossRef
30.
Zurück zum Zitat Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27–55.PubMedCrossRef Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27–55.PubMedCrossRef
32.
Zurück zum Zitat Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis. 2002;61:960–7.PubMedCrossRef Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis. 2002;61:960–7.PubMedCrossRef
33.
Zurück zum Zitat Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004;3:330–9.PubMedCrossRef Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004;3:330–9.PubMedCrossRef
34.
Zurück zum Zitat Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol. 1992;62:S60–5.PubMedCrossRef Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol. 1992;62:S60–5.PubMedCrossRef
35.
Zurück zum Zitat Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther. 2010;87:483–7.PubMedCrossRef Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther. 2010;87:483–7.PubMedCrossRef
36.
Zurück zum Zitat Molto A, Olive A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine. 2010;77:102–7.PubMedCrossRef Molto A, Olive A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine. 2010;77:102–7.PubMedCrossRef
37.
Zurück zum Zitat Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, Kang SS, et al. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Eur J Pharmacol. 2008;586:340–9.PubMedCrossRef Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, Kang SS, et al. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Eur J Pharmacol. 2008;586:340–9.PubMedCrossRef
Metadaten
Titel
Methyl-1-hydroxy-2-naphthoate, a novel naphthol derivative, inhibits lipopolysaccharide-induced inflammatory response in macrophages via suppression of NF-κB, JNK and p38 MAPK pathways
verfasst von
Jun-Yan Zhang
Hong Jin
Guang-Fa Wang
Peng-Jiu Yu
Shao-Yu Wu
Zheng-Guang Zhu
Zhong-Huang Li
Yuan-Xin Tian
Wei Xu
Jia-Jie Zhang
Shu-Guang Wu
Publikationsdatum
01.09.2011
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 9/2011
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-011-0345-2

Weitere Artikel der Ausgabe 9/2011

Inflammation Research 9/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.